FDA Grants Fast Track Designation To Lundbeck For Narcolepsy Therapy Lu AH69593

H. Lundbeck reported it received FDA Fast Track designation for Lu AH69593, its investigational narcolepsy treatment. The milestone is a regulatory positive that may support faster development and review, but no efficacy or financial guidance details were provided.

Analysis

H. Lundbeck reported it received FDA Fast Track designation for Lu AH69593, its investigational narcolepsy treatment. The milestone is a regulatory positive that may support faster development and review, but no efficacy or financial guidance details were provided.